BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sulkowski MS, Feld JJ, Lawitz E, Felizarta F, Corregidor AM, Khalid O, Ghalib R, Smith WB, Van Eygen V, Luo D, Vijgen L, Gamil M, Kakuda TN, Ouwerkerk-Mahadevan S, Van Remoortere P, Beumont M. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. J Viral Hepat 2018;25:631-9. [PMID: 29274193 DOI: 10.1111/jvh.12853] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Zeuzem S, Bourgeois S, Greenbloom S, Buti M, Aghemo A, Lampertico P, Janczewska E, Lim SG, Moreno C, Buggisch P, Tam E, Corbett C, Willems W, Vijgen L, Fevery B, Ouwerkerk-Mahadevan S, Ackaert O, Beumont M, Kalmeijer R, Sinha R, Biermer M; OMEGA-1 study team. JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology 2019;69:2349-63. [PMID: 30693573 DOI: 10.1002/hep.30527] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Chua JV, Ntem-Mensah A, Abutaleb A, Husson J, Mutumbi L, Lam KW, Ghosh A, Romani S, Poonia B, Lee S, Luz Pascual M, Frumkin LR, Kottilil S. Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study. J Med Virol 2021;93:3752-60. [PMID: 33150966 DOI: 10.1002/jmv.26652] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Brown RS, Buti M, Rodrigues L, Chulanov V, Chuang W, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin C, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial. Journal of Hepatology 2020;72:441-9. [DOI: 10.1016/j.jhep.2019.10.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 23.5] [Reference Citation Analysis]
4 Li H, Tan JL, Li JR, Liu NN, Chen JH, Lv XQ, Zou LL, Dong B, Peng ZG, Jiang JD. A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens. Biomed Pharmacother 2019;116:108976. [PMID: 31103827 DOI: 10.1016/j.biopha.2019.108976] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Said EM, Abdulaziz BA, El Kassas M, El Attar IH, Emadeldeen M, Abd-Elsalam SM. High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Arch Virol 2020;165:1633-9. [PMID: 32356185 DOI: 10.1007/s00705-020-04639-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kakizoe Y, Koizumi Y, Ikoma Y, Ohashi H, Wakita T, Iwami S, Watashi K. Required concentration index quantifies effective drug combinations against hepatitis C virus infection. Theor Biol Med Model 2021;18:4. [PMID: 33422060 DOI: 10.1186/s12976-020-00135-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. [PMID: 31754636 DOI: 10.12688/wellcomeopenres.15411.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
8 Huang M, Li H, Xue R, Li J, Wang L, Cheng J, Wu Z, Li W, Chen J, Lv X, Li Q, Lan P, Zhao L, Yang Y, Peng Z, Jiang J. Up-regulation of glycolipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication. Acta Pharmaceutica Sinica B 2019;9:769-81. [DOI: 10.1016/j.apsb.2019.01.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]